Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Cannon CP, et al. Among authors: mueller hs. Circulation. 1998 Feb 3;97(4):340-9. doi: 10.1161/01.cir.97.4.340. Circulation. 1998. PMID: 9468207 Clinical Trial.
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, et al. Cannon CP, et al. Among authors: mueller hs. J Am Coll Cardiol. 1994 Apr;23(5):993-1003. doi: 10.1016/0735-1097(94)90581-9. J Am Coll Cardiol. 1994. PMID: 8144799 Free article. Clinical Trial.
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. Cannon CP, et al. Among authors: mueller hs. Circulation. 1998 Dec 22-29;98(25):2805-14. doi: 10.1161/01.cir.98.25.2805. Circulation. 1998. PMID: 9860780 Clinical Trial.
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial.
Gibson CM, Zorkun C, Molhoek P, Zmudka K, Greenberg M, Mueller H, Wesdorp J, Louwerenburg H, Niederman A, Westenburg J, Bikkina M, Batty J, de Winter J, Murphy SA, McCabe CH. Gibson CM, et al. J Thromb Thrombolysis. 2006 Aug;22(1):13-21. doi: 10.1007/s11239-006-8080-1. J Thromb Thrombolysis. 2006. PMID: 16786228 Clinical Trial.
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM. Kizer JR, et al. Among authors: mueller hs. Am Heart J. 1999 Jan;137(1):79-92. doi: 10.1016/s0002-8703(99)70462-x. Am Heart J. 1999. PMID: 9878939
Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy.
Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA, Sokol S, Braunwald E, Mueller HS. Srinivas VS, et al. Among authors: mueller hs. Am Heart J. 2001 Jul;142(1):29-36. doi: 10.1067/mhj.2001.116068. Am Heart J. 2001. PMID: 11431653 Clinical Trial.
100 results